The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting now
Conditions studied: Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
In brief
There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This study aims to characterize the impact of palliative care versus biopsy versus resection on survival and quality of life in these patients. Also, it will aim to determine if there is a subset of patients that benefit the most from resection or biopsy, for which outcome, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 3-arm cohort study of observational nature. Consecutive HGG patients will be treated with palliative care, biopsy, or resection at a 1:3:3 ratio. Primary endpoints are: 1) overall survival, and 2) quality of life at 6 weeks, 3 months and 6 months after initial presentation based on the EQ-5D, EORTC QLQ C30 and EORTC BN 20 questionnaires. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.
Key facts
- Study ID
- NCT06146738
- Run by
- Jasper Gerritsen
- People needed
- 1015
- Starts
- 2023-01-01
- Expected to finish
- 2029-01-01
- Last updated by the study team
- 2023-11-27
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18 years and ≤90 years
- Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
- Written informed consent
You may not qualify if…
- Tumors of the cerebellum, brainstem or midline
- Inability to give written informed consent
- Secondary high-grade glioma due to malignant transformation from low-grade glioma
- Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin
Where it is running
- University of California, San Francisco — San Francisco, California, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- University Hospital Leuven — Leuven, Belgium (enrolling)
- Erasmus Medical Center — Rotterdam, South Holland, Netherlands (enrolling)
- Haaglanden Medical Centre — The Hague, South Holland, Netherlands (enrolling)
- University Hospital Heidelberg — Heidelberg, Germany (enrolling)
- Technical University Munich — Munich, Bavaria, Germany
- Inselspital Universitätsspital Bern — Bern, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.